Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD

Mild Cognitive Impairment Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02225964
• Other study ID #: XuanwuH 2
• Status: Completed
• Start date: January 2014
• Est. completion date: December 2018

Study information

• Verified date: June 2020
• Source: Xuanwu Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is to find out the imaging marker and the changing laws of the marker during the course of the disease. The final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of Alzheimer's disease.

Description:

It is an urgent problem in the field of cognitive neuroscience to tell the conversion progression of amnestic mild cognitive impairment(aMCI) patients with Apolipoproteinε4(APOEε4) to Alzheimer's Disease(AD). Based on our preliminary work, we will study the special group of aMCI patients with APOEε4 with multi-modality magnetic resonance imaging (resting-state functional MRI, structural MRI and diffusion tensor imaging) longitudinally. Besides, we will also detect the APOE genotype of each sample and enlarge the sample size. According to situation of the conversion or non-conversion and differences in the conversion progression, we will analyze the data between the inter-groups and intra-groups, compare the imaging data of baseline and follow-up, find the prediction imaging marker of AD and optimize the reliability and validity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: December 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Complaint about memory loss and confirmed by an informant

• Cognitive impairment in single or multiple domains, adjusted for age and education

• Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities

• A Clinical Dementia Rating (CDR) score is 0.5

• Failure to meet the criteria for dementia

• Carrying susceptible gene APOEe4

• Must be able to accept examination of MRI, sight and hearing allow to complete test

Exclusion Criteria:

• Other diseases that cause cognitive impairment,such as thyroid disease,stroke and so on

• people who have severe visual and hearing impairment

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment

Locations

Country	Name	City	State
China	Department of Neurolgy,Xuanwu Hospital of Capital Medical University	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
XuanwuH 2	Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the conversion of aMCI patients with APOEe4 to AD	According to situation of the conversion or non-conversion and differences in the conversion progression, we will analyze the data between the inter-groups and intra-groups, compare the imaging data of baseline and follow-up, find the prediction imaging marker of AD and optimize the reliability and validity.	one year